- Conditions
- Alcohol Use Disorder
- Interventions
- gabapentin enacarbil, Placebo
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pain, Postoperative, Spine Injuries and Disorders, Narcotic Use
- Interventions
- Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended Release, Placebo
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
- Conditions
- RLS
- Interventions
- HORIZANT 600 mg
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 11
- States / cities
- Redwood City, California • San Diego, California • Gulf Breeze, Florida + 8 more
- Conditions
- Restless Legs Syndrome, Restless Legs Syndrome (RLS)
- Interventions
- GSK1838262 Extended Release Tablets, Placebo
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 24
- States / cities
- Jasper, Alabama • San Diego, California • Hallandale, Florida + 20 more
- Conditions
- Restless Legs Syndrome
- Interventions
- morphine Placebo, GEn 600 mg, Morphine, GEn Placebo
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- RLS
- Interventions
- HORIZANT 300 mg
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
- Conditions
- RLS
- Interventions
- HORIZANT 300 mg, HORIZANT 600 mg, Placebo
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 12
- States / cities
- Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
- Conditions
- Opioid Use, Pain, Femoral Acetabular Impingement, Labral Tear, Glenoid
- Interventions
- Control Group Regimen, Opioid reduced regimen
- Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Restless Leg Syndrome
- Interventions
- Gabapentin immediate release, Gabapentin enacarbil extended release
- Drug
- Lead sponsor
- Theresa Zesiewicz, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Neuralgia, Postherpetic
- Interventions
- Gabapentin extended-release tablets
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Neuralgia,Postherpetic
- Interventions
- Gabapentin Extended Release tablets, Placebo
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended Release tablets, Gabapentin
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 8
- States / cities
- Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more
- Conditions
- Restless Legs Syndrome
- Interventions
- Gabapentin Enacarbil (GEn), Placebo
- Drug
- Lead sponsor
- Cleveland Sleep Research Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Middleburg Heights, Ohio